SCHEMBL2292166

SCHEMBL2292166

COc1ccc(OCC(N)=O)c(-c2nc3ccccn3c2Nc2c(C)cccc2C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 7/20 0.48
MAPT P10636 7/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PKM P14618 1/20 0.47
PKLR P30613 1/20 0.47
TUBB4A P04350 4/20 0.47
TUBB P07437 4/20 0.47
TUBA3C P0DPH7 4/20 0.47
TUBA1B P68363 4/20 0.47
TUBA4A P68366 4/20 0.47
TUBB4B P68371 4/20 0.47
TUBB3 Q13509 4/20 0.47
TUBB2A Q13885 4/20 0.47
TUBB8 Q3ZCM7 4/20 0.47
TUBA3E Q6PEY2 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2291890 0.93 GAA (0.48) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2289177 0.90 GAA (0.51) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2289780 0.90 GAA (0.50) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2290324 0.89 GAA (0.49) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2289489 0.89 GAA (0.49) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2288504 0.88 GAA (0.54) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2291131 0.88 ADRA1B (0.44) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2290147 0.87 GAA (0.46) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2288553 0.86 MAPT (0.48) GAAMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL2292123 0.86 MAPT (0.46) GAAMAPTSMN1; SMN2KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 GAA 1202/4885MAPT 1138/4885SMN1; SMN2 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.